Literature DB >> 16156050

Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry.

Bankole A Johnson1, Karl Mann, Mark L Willenbring, Raye Z Litten, Robert M Swift, Otto M Lesch, Mats Berglund.   

Abstract

This article represents the proceedings of a symposium presented at the 12th Congress of the International Society for Biomedical Research on Alcoholism held in Heidelberg/Mannheim, Germany, on September 30, 2004. The organizers and cochairs were Bankole A. Johnson, DSc, MD, PhD, and Karl Mann, MD. The presentations included the following: (1) A Perspective from Academia, by Bankole A. Johnson, DSc, MD, PhD; (2) A Perspective from NIAAA, by Mark L. Willenbring, MD; (3) A Perspective from US Clinical Practice, by Robert M. Swift, MD, PhD; (4) A European Perspective on Medications Development, by Otto M. Lesch, MD, PhD, and (5) A Scandinavian Perspective on Evidence-Based Addiction Treatment, by Mats Berglund, MD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16156050     DOI: 10.1097/01.alc.0000174690.63787.fc

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  5 in total

Review 1.  Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.

Authors:  Bankole A Johnson; Nassima Ait-Daoud
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 2.  Medications development to treat alcohol dependence: a vision for the next decade.

Authors:  Raye Z Litten; Mark Egli; Markus Heilig; Changhai Cui; Joanne B Fertig; Megan L Ryan; Daniel E Falk; Howard Moss; Robert Huebner; Antonio Noronha
Journal:  Addict Biol       Date:  2012-03-28       Impact factor: 4.280

Review 3.  Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Authors:  Bankole A Johnson
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

4.  Contribution of ventral tegmental GABA receptors to cocaine self-administration in rats.

Authors:  E N Backes; S E Hemby
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

5.  Naltrexone long-acting formulation in the treatment of alcohol dependence.

Authors:  Bankole A Johnson
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.